Imaging Glioblastoma Response to Radiotherapy Using (2)H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism

Early detection of tumor cell death in glioblastoma following treatment with chemoradiation has the potential to distinguish between true disease progression and pseudoprogression. Tumor cell death can be detected noninvasively in vivo by imaging the production of [2,3-(2)H(2)]malate from [2,3-(2)H(2)]fumarate using (2)H magnetic resonance (MR) spectroscopic imaging. We show here that (2)H MR spectroscopy and spectroscopic imaging measurements of [2,3-(2)H(2)]fumarate metabolism can detect tumor cell death in orthotopically implanted glioblastoma models within 48 hours following the completion of chemoradiation. Following the injection of [2,3-(2)H(2)]fumarate into tumor-bearing mice, production of [2,3-(2)H(2)]malate was measured in a human cell line–derived model and in radiosensitive and radioresistant patient-derived models of glioblastoma that were treated with temozolomide followed by targeted fractionated irradiation. The increase in the [2,3-(2)H(2)]malate/[2,3-(2)H(2)]fumarate signal ratio posttreatment, which correlated with histologic assessment of cell death, was a more sensitive indicator of treatment response than diffusion-weighted and contrast agent–enhanced (1)H MRI measurements, which have been used clinically to detect responses of glioblastoma to chemoradiation. Overall, early detection of glioblastoma cell death using (2)H MRI of malate production from fumarate could help improve the clinical evaluation of response to chemoradiation. SIGNIFICANCE: (2)H magnetic resonance imaging of labeled fumarate metabolism can detect early evidence of tumor cell death following chemoradiation, meeting a clinical need to reliably detect treatment response in glioblastoma.